Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Original Research

Accepted on 09 Jun 2025

Adverse event profile of five anti Head and Neck Squamous Cell Carcinoma drugs: a descriptive analysis from WHO-VigiAccess

in Pharmacology of Anti-Cancer Drugs

Weimin Gao
Zhigang Xia
Tingfeng Zhou
Youlin Dong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1602276

Systematic Review

Published on 09 Jun 2025

Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis

in Pharmacology of Anti-Cancer Drugs

Chengjun Wang
Chuang Yang
Wen Zhao
Rongyu Zhang
Tiantian Xuan
Jisheng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1539246

325 views

Original Research

Published on 09 Jun 2025

An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib

in Pharmacology of Anti-Cancer Drugs

Wenjuan Wang
Hong Liu
Yongqing Wen
Yanhua Zhang
Xu Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1619517

272 views

Original Research

Published on 09 Jun 2025

Structure-based molecular screening and dynamic simulation of phytocompounds targeting VEGFR-2: a novel therapeutic approach for papillary thyroid carcinoma

in Pharmacology of Anti-Cancer Drugs

Shuai Wang
Lingqian Zhang
Wenjun Zhang
Xiong Zeng
Jie Mei
Weidong Xiao
Lijie Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1583329

200 views

Original Research

Published on 09 Jun 2025

The type I ribosome-inactivating protein α-MMC induced significant apoptosis of lung cancer A549 and 95-D cells by activating the caspase cascade through TNF signaling pathway

in Pharmacology of Anti-Cancer Drugs

Di Yang
Di Peng
Houke Li
Di Jia
Yiping Zhou
Bintao Hu
Wei Chen
Yao Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1529151

239 views

Systematic Review

Accepted on 05 Jun 2025

Efficacy and Safety of Serplulimab in Solid Tumors: A Meta-Analysis

in Pharmacology of Anti-Cancer Drugs

Peimeng Shen
Tao Zhang
Lina Hao
Ming Jing
Yanxin Wu
Shuwen Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1604874

Original Research

Accepted on 05 Jun 2025

Efficacy and Safety of Darolutamide versus Abiraterone Acetate plus Prednisone in Combination with ADT for mHSPC: A Real-World Clinical Retrospective Study

in Pharmacology of Anti-Cancer Drugs

Ting Hu
Fang Zhou
Yang Zheng
Bohan Luo
Yongliang Zhang
Chengpeng Gu
Guopeng Wang
Jinze Zhang
Jingzhi Tian
Yu Nie

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1608339

Original Research

Accepted on 05 Jun 2025

Exploration on M2 macrophage-related biomarkers and candidate drug for glioblastoma using high-dimensional weighted gene co-expression network analysis

in Pharmacology of Anti-Cancer Drugs

Suyin Feng
Long Zhu
Jinyuan Gu
Kun Kou
Yongtai Liu
Guangmin Zhang
Hua Lu
Honglai Zhang
Runfeng Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1587258

Original Research

Published on 05 Jun 2025

Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo

in Pharmacology of Anti-Cancer Drugs

Essha Chatterjee
Ram Sharma
Biswajit Dey
Hoshiyar Singh
Aliva Naik
Anjesh Khan
Santanu Basak
Ankush Bansode
Ritika Sachdeva
Anamika Sharma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1544666

726 views

Case Report

Published on 05 Jun 2025

Case Report: Osimertinib-induced acute interstitial lung disease

in Pharmacology of Anti-Cancer Drugs

Zhiwu Lin
Liang Wu
Yang Yu
Jiudong Jiang
Yanchun Yang
Guibao Xiao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1608733

404 views

Mini Review

Published on 05 Jun 2025

Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications

in Pharmacology of Anti-Cancer Drugs

Chengwei Li
Xiaoyan Qi
Min Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572195

418 views

Review

Published on 04 Jun 2025

Role and therapeutic potential of the NEDD4 family in breast cancer

in Pharmacology of Anti-Cancer Drugs

Xiaoxiao Zhang
Sijie Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1587675

269 views

Original Research

Published on 04 Jun 2025

SPAG6 Promotes Multiple Myeloma Through Activation of the MAPK/ERK Signaling Pathway

in Pharmacology of Anti-Cancer Drugs

Junnan Li
Xinyu Yan
Li Ding
Jiaxiu Yin
Ping Li
Lin Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572621

350 views

Original Research

Published on 04 Jun 2025

Pomolic acid induces ferroptosis-mediated cell death in non-small cell lung cancer

in Pharmacology of Anti-Cancer Drugs

Wenbin Ji
Yanbin Zhang
Wenhao Ji
Hui Zhang
Biao Qin
Xiao-Liang Xing
Zaiqi Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1567942

486 views

Original Research

Accepted on 03 Jun 2025

Glycyrrhiza uralensis Fisch. Suppresses Cell Migration via ROS and JAK/STAT Signalling Pathways in Drosophila

in Pharmacology of Anti-Cancer Drugs

Fangfei Zhou
Meng Zhao
Yue Hu
Lingyu Kong
Sitong Wang
Haixia Zhang
Qingge Lu
Fanwu Wu
Chenxi Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1549920

117 views

Retraction

Accepted on 03 Jun 2025

Retraction: Eupalinolide J Suppresses the Growth of Triple-Negative Breast Cancer Cells via Targeting STAT3 Signaling Pathway

in Pharmacology of Anti-Cancer Drugs

Frontiers Editorial Office

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1639679

124 views